Growth finance for Series B companies: scaling without breaking for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install growth finance has to reflect that reality from day one.

Series B is the stress test for growth finance. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, CAC payback and gross margin, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Growth finance is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of growth finance is optimising for growth rate at any cost, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on CAC payback and gross margin outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run growth finance function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing growth finance properly rather than half-heartedly across three vendors.